RxDoctor Payments Data

Anthony Horton, DO

Family Medicine · Sheffield, ALNPI 1427618073

Payments from drug & device makers

$1,598in general payments, 2019–2025

Across 104 payments — averaging $15.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$530
  • Lilly USA, LLC$258
  • Pfizer$136
  • AstraZeneca$130
  • AbbVie$98
  • Bayer$70
  • plus $377 from 15 others

What the payments were for

  • Food & beverage$1,598100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,598 in reported general payments places this provider in the 65th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$401,666
Medicare patients
720
Services billed
23,748

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide278$354,986
MounjaroTirzepatide184$265,985
EliquisApixaban292$265,788
FarxigaDapagliflozin Propanediol166$163,387
JardianceEmpagliflozin162$154,573
TrulicityDulaglutide96$123,058
XareltoRivaroxaban95$96,094
Trelegy ElliptaFluticasone/Umeclidin/Vilanter84$74,537
JanuviaSitagliptin Phosphate53$67,607
RybelsusSemaglutide43$55,514
Tresiba Flextouch U-200Insulin Degludec53$50,714
Repatha SyringeEvolocumab54$50,471
EntrestoSacubitril/Valsartan34$29,498
Repatha SureclickEvolocumab37$26,978
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$26,009

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$530$410,500321 claims
Lilly USA, LLCMounjaro, Trulicity$258$389,043280 claims
PfizerEliquis, Premarin$136$274,487314 claims
AstraZenecaFarxiga, Breztri Aerosphere$130$189,396185 claims
Boehringer IngelheimJardiance$16$154,573162 claims
GSKTrelegy Ellipta, Anoro Ellipta$27$82,137100 claims
MerckJanuvia$16$67,60753 claims
AbbVieLinzess$98$19,53432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Sheffield

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →